Does PIRTOBRUTINIB Cause Malignant neoplasm progression? 43 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 43 reports of Malignant neoplasm progression have been filed in association with PIRTOBRUTINIB (JAYPIRCA). This represents 9.8% of all adverse event reports for PIRTOBRUTINIB.
43
Reports of Malignant neoplasm progression with PIRTOBRUTINIB
9.8%
of all PIRTOBRUTINIB reports
33
Deaths
23
Hospitalizations
How Dangerous Is Malignant neoplasm progression From PIRTOBRUTINIB?
Of the 43 reports, 33 (76.7%) resulted in death, 23 (53.5%) required hospitalization, and 3 (7.0%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PIRTOBRUTINIB. However, 43 reports have been filed with the FAERS database.
What Other Side Effects Does PIRTOBRUTINIB Cause?
Death (65)
Disease progression (41)
Pneumonia (41)
Anaemia (27)
Chronic lymphocytic leukaemia (25)
Pancytopenia (22)
Off label use (21)
Drug ineffective (20)
White blood cell count increased (19)
Covid-19 (18)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which PIRTOBRUTINIB Alternatives Have Lower Malignant neoplasm progression Risk?
PIRTOBRUTINIB vs PIT VIPER IMMUNE GLOBULIN ANTIVENIN
PIRTOBRUTINIB vs PITAVASTATIN
PIRTOBRUTINIB vs PITOLISANT
PIRTOBRUTINIB vs PIXANTRONE
PIRTOBRUTINIB vs PIZOTYLINE